Validation of column-based chromatograhy processes for the purification of proteins

PDA Journal of Pharmaceutical Science and Technology

Volumn 62, Issue SUPPL. 3, 2008, Pages 1-33

  Brandeth, E J ^a   Bussineau, Chris ^b   Butler, Michelle ^c   Christensen, Tony ^d   Conrad, Doris ^e   Devine, Becky ^d   Godavarti, Ranga ^d   Grund, Eric ^f   Hentschel, Norbert ^g   Lester, Philip ^h   McNay, Jennifer ⁱ   Muegge, Michael ^j   Notarnicola, Stephen ^k   Patel, Rahul ^l   Scaggs, Laurie ^m  

^a Favrille Inc

^b BioVascular Inc

^c GENENTECH INC   (United States)

^d Scantago ApS ^*

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^f GE HEALTHCARE   (United Kingdom)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^h REGENERON PHARMACEUTICALS INC   (United States)

ⁱ Bayer Healthcare Association

^j BIOGEN   (United States)

^k IMMUNOMEDICS INC   (United States)

^l AMGEN INC   (United States)

^m ABBOTT LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DECISION MAKING; DOCUMENTATION; MATHEMATICAL MODEL; PROCESS CONTROL; PROCESS DESIGN; PROCESS DEVELOPMENT; PROCESS TECHNOLOGY; PROTEIN PURIFICATION; QUALITY CONTROL; RISK ASSESSMENT; SEPARATION TECHNIQUE; VALIDATION PROCESS;

EID: 56849111796     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Technical Report No. 42: Process Validation of Protein Manufacturing; Parenteral Drug Association: Bethesda, MD, 2005.
2. Quality Guideline Q7A: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. International Conference on Harmonisation: 2000.
3. Quality Guideline Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. International Conference on Harmonisation: 1999.
4. Quality Guideline Q1A(R2): Stability Testing of New Drug Substances and Products (Second Revision). International Conference on Harmonisation: 2003.
5. Sofer, G.; Hagel, L. Handbook of Process Chromatography; Academic Press: San Diego, CA, 1997.
6. Scopes, R.K. Protein Purification: Principles and Practice, 3rd Ed.; Springer Science+Business Media, Inc: New York, 1994.
7. Gagnon, P. Purification Tools for Monoclonal Antibodies; Validated Biosystems: San Clemente, 1996.
8. Haaland, P. Experimental Design in Biotechnology; Marcel Dekker: New York, 1989.
9. Kelley, B. D. Establishing process robustness using designed experiments. In Biopharmaceutical Process Validation; Sofer, G., Zabriskie, D., Eds.; Marcel Dekker: New York, 2000.
10. Box, George E.P.; Hunter, W.G.; Hunter, J.S. Statistics for Experimenters: An Introduction to Design, Data Analysis, and Model Building; John Wiley & Sons: Hoboken, NJ, 1978.
11. Mollah, H. A. Risk Analysis and Process Validation. BioPro. Internat. 2004 2 (9), 28-35.
12. Quality Guideline Q9: Quality Risk Management. International Conference On Harmonisation: 2005.
13. Quality Guideline Q8: Pharmaceutical Development. International Conference On Harmonisation: 2005.
14. Kidal, S.; Jensen O.E. Using Volumetric Flow to Scaleup Chromatographic Processes. BioPharm. Internat., 2006, 19(3), 34-43.
15. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. US Food and Drug Administration: 1997.
16. Curtis, S.; Lee, K.; Blank, G.S.; Brorson, K.; Xu, Y. Generic/matrix evaluation of SV40 clearance by anion exchange chromatography in flow-through mode. Biotechnol. Bioeng. 2003, 84, 179-186.
17. Brorson, K.; Krejci S.; Lee, K.; Hamilton E.; Stein K.; Xu, Y. Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotech. Bioeng. 2003, 82, 321-329.
18. Larson T.M.; Davis J.; Lam, H.; Cacia, J. Use of Process Data To Assess Chromatographic Performance in Production-Scale Protein Purification Columns. Biotechnol. Prog., DOI: 10.1021/bp025639g. Published Online: Nov 6, 2002. http://pubs.acs.org/cgi-bin/abstract.cgi/bipret/2003/19/i02/ abs/bp025639g.html.
19. Larson T.M.; Davis J.; Lam, H.; Cacia, J. Use of Process Data To Assess Chromatographic Performance in Production-Scale Protein Purification Columns. Biotechnol. Prog., 2003, 19, 485-492, 2003.
20. Quality Guideline Q5A: Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology products derived From Cell Lines of Human or Animal Origin. International Conference on Harmonization: 1997.
21. Scale-up and optimization in Preparative Chromatography: Principles and Biopharmaceuticals Velayuphan; A., Rathore, A., Eds.; Chromatographic Science Series. Marcel Dekker, Inc.: New York, 2003; Vol. 88.
22. Rathore, A.S.; Krishnan, R.; Tozer, S.; Smiley, D.; Rausch, S.; Seely, J. Scaling Down of Biopharmaceutical Unit Operations, Part II: Chromatography and Filtration. BioPharm. Internat. 2005, 18(5), 58-64.
23. Rathore, A.S.; Velayudhan, A. Scale-up Guidelines for Preparative Chromatography. Biopharm. Internat. 2003, 16(1), 34-42.
24. Shi L.; Chen Q.; Norling L.A.; Lau A.S.L.; Krejci S.; Xu Y. Real time quantitative PCR as a method to evaluate xenotropic murine leukemia virus removal during pharmaceutical protein purification. Biotechnol. and Bioeng. 2004, 87, 884-96.
25. Henzler, H.; Kaiser, K. Avoiding viral contamination in biotechnological and pharmaceutical processes. Nature Biotechnol. 1998, 16, 1077-1079.
26. Brorson, K.; Brown, J.; Hamilton, P.; Stein, K. Identification of protein A media performance attributes that can be monitored as surrogates for retrovirus clearance during extended re-use. J Chromatogr, A. 2003, 989, 155-163.
27. Norling, L.; et al. Impact of Multiple Re-Use of Anion-Exchange Chromatography Media on Virus Removal. J. Chromatogr., A. 2005, 1069, 79-89.
28. Valera, C.R.; Chen, J.W.; Xu, Y. Application of multivirus spike approach for viral clearance evaluation. Biotechnol. & Bioeng. 2003, 84, 714-722.
29. Seely, J. E.; Seely, R. J. A rational, step-wise approach of process characterization. BioPharm Internat. 2003, 16 (8), 24-34.
30. Berry, I.; Harpaz, D. Validation of Active Pharmaceutical Ingredients, 2nd ed.; CRC Press: Boca Raton, FL, 2001.
31. Biopharmaceutical Process Validation; Sofer, G., Zabriskie, D., Eds.; Marcel-Dekker Press: New York, 2000.
32. Technical Report No. 38: Manufacturing Chromatography Systems Postapproval Changes (ChromPACs): Chemistry, Manufacturing, and Controls Documentation; Parenteral Drug Association: Bethesda, MD, 2005.
33. Protein Purification Handbook, 18-1132; GE Healthcare, 2007.
34. Gebauer, K.; Thömmes, J.; Kula, M.R. Plasma Protein Fractionation with Advanced Adsorbents. Biotechnol. Bioeng. 1997, 54, 181-189.
35. Ion Exchange Chromatography & Chromatofocusing: Principles and Methods, 11-0004-21; GE Healthcare, 2002.
36. Antibody Purification Handbook, 18-1037-46; GE Healthcare, 2003.
37. Purifying Challenging Proteins: Principles and Method, 20-9095-31; GE Healthcare, 2007.
38. Hydrophobic Interaction Chromatography and Reversed Phase Chromatography, 11-0012-69; GE Healthcare, 2006.
39. Gel Filtration: Principles and Methods, 18-1022-18; GE Healthcare, 2007.
40. Mason, R.; Gunst, R.; Hess, J. Statistical Design and Analysis of Experiments, with Applications to Engineering and Science, 2nd Ed.; John Wiley & Sons: Hoboken, NJ, 2003.
41. Juran, J.M.; Godfrey, A.B. Juran's Quality Handbook, 5th Ed.; McGraw-Hill: New York, 1999.
42. See box Evaluating the Potential Impact of Process-Related Impurities on Product Quality, In "The Gold Sheet", 2004, 38 (9).
43. Steindl F.; et. al. A simple method to quantify staphylococcus protein A in the presence of human or animal IgG in various samples. J. immunol. Methods 2000, 235, 61-69.
44. Baseline Guide: Volume 5 - Commissioning and Qualification; International Society for Pharmaceutical Engineering: Tampa, FL, 2005.